The activity of fluconazole, amphotericin B, caspofungin and micafungin was determined using XTT-based fungal damage assays against planktonic cells, early and mature biofilms of Candida kefyr. Median MICs of planktonic cells were 0.25 mg/l, 0.25 mg/l, 0.5 mg/l, and 0.06 mg/l for fluconazole, amphotericin B, caspofungin, and micafungin, respectively. Fluconazole showed at least 50% fungal damage at ≥4 mg/l (51.5% ± 6.63% to 78.38% ± 1.44%) and at ≥128 mg/l (57.88% ± 9.2% to 67.25% ± 9.59%), while amphotericin B produced an even higher anti-biofilm effect at ≥0.5 mg/l (64.63% ± 6.79% to 79.5% ± 5.9%) and at ≥0.12 mg/l (77.63% ± 8.43% to 92.75% ± 1.89%) against early and mature biofilms, respectively. In case of micafungin, 50% fungal damage was observed at ≥0.06 mg/l (66.88% ± 10.16% to 98.63% ± 1.24%) and ≥0.25 mg/l (74.13% ± 10.77% to 99.38% ± 0.38%) for early and mature biofilms, respectively. Caspofungin-exposed cells showed an unexpected susceptibility pattern, that is, planktonic cells showed significantly decreased susceptibility at concentrations ranging from 0.015 mg/l to 1 mg/l compared to biofilms (P < .05-.01). The damage in planktonic cells and biofilms was comparable at higher concentrations. For planktonic cells and biofilms, 50% fungal damage was observed first at 0.5 mg/l (59.75% ± 3.16%) and at 0.06 mg/l (70.25% ± 10.95%), respectively. This unexpected pattern was confirmed using scanning electron microscopy. The unusual susceptibility pattern observed at lower caspofungin concentrations may explain the poorer outcome of caspofungin-treated C. kefyr infections documented in certain patient populations. As this phenomenon was markedly less apparent in case of micafungin, these data suggest that micafungin may be a more reliable option than caspofungin for the treatment of C. kefyr infections.
Introduction
Candida kefyr is an emerging problem, especially among immuncompromised patients with haematological disorders. [1] [2] [3] [4] In patients with hematological malignancies, the prevalence of infections by C. kefyr is 4.1% and 9.9% in the intensive care unit and in normal wards, respectively. 3 Based on a retrospective study from the United
States, the incidence of colonization is the highest among patients with acute myelogenous leukemia receiving induction chemotherapy (8.7%). 1 The 30-day mortality rate caused by C. kefyr is higher than that of C. albicans. 3 In addition, C. kefyr may have a remarkable role in catheter-related infections; Seidler et al. 5 observed fourfold higher adhering affinity to polystyrene surfaces compared to C. albicans cells. The optimal treatment against C. kefyr is not well defined so far, because clinical isolates frequently show lower in vitro susceptibility as compared to epidemiological cutoff values (ECVs) of antifungals, especially in case of echinocandins. [1] [2] 6 Acquired echinocandin resistance can develop even within 10 days of treatment by appearance of specific mutations in the hot-spot 1 region of CkFKS1 gene. [7] [8] Nevertheless, the unusual rapidity of the development of resistance in case of C. kefyr remains to be explained. Until recently, little was known on the susceptibility pattern of C. kefyr biofilms regarding the most frequently administered systemic antifungals, in spite of the high mortality rate and its potential role in catheter-related infections. To extend our knowledge about the in vitro activity of traditional systemic antifungals against C. kefyr, the susceptibility of planktonic cells to fluconazole, amphotericin B, caspofungin, and micafungin was compared to the susceptibility of early stage and mature biofilms.
Methods

Fungal isolates
Ten clinical C. kefyr isolates derived from blood, urine, throat, bronchus, and abdominal samples isolated between January 2013 and December 2016 were studied. All isolates were from antifungal-naïve patients. Clinical isolates were identified by MALDI/TOF (Microflex, Bruker Daltronics, Bremen, Germany) and by API ID32C (bioMérieux, Marcyl'Étoile, France) panel according to the manufacturer's instructions. For comparison, C. albicans SC5314 reference strain was also tested.
Biofilm formation
In sum, 1-day-old (early) and 3-day-old (mature) biofilms were prepared as described by Pierce et al. 9 and Kovács et al. 10 Briefly, aliquots of 100 µl of standardized C. The in vitro activity of different antifungals against planktonic and sessile cells was assessed using XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) reduction assay as described previously. [9] [10] [13] [14] After the incubation period, plates were washed 3 times with physiological saline, and then a 100 µl aliquot of XTT/menadione solution (0.5 g/l XTT supplemented with 1 µM menadione; Sigma, Budapest, Hungary) was added to each well containing the washed planktonic cells or preformed washed biofilms. Plates were covered and were incubated in darkness for 2 h at 37 • C. After the incubation time, 80 µl of supernatant from each well 1 MIC is offscale at >512 mg/l, 1024 mg/l (one dilution higher than the highest tested concentration) was used for median calculation was measured spectrophotometrically at 492 nm with a reference wavelength of 620 nm. [9] [10] 14 Antifungal activity was calculated based on this formula: fungal damage (%) = [1−(absorbance of experimental cells/absorbance of control wells)] × 100. Minimum inhibitory concentrations (MICs) of planktonic cells and biofilms were defined based on fungal damage. MIC being the lowest drug concentration that caused at least 50% fungal damage compared to the untreated control well. 15 All isolates were tested at least twice in three independent experiments for each antifungal drug. The damage caused on planktonic cells and biofilms was compared by calculating the mean damage measured for individual isolates ± standard error of the mean.
Scanning electron microscopy
Morphology of planktonic cells, 1-day-old biofilms and 3-day-old biofilms derived from one representative C. kefyr isolate 15879 was examined after 0.12 mg/l caspofungin exposure due to an observed unexpected susceptibility pattern. For planktonic cells, fungal cell suspension was diluted 100-fold, and a smear was prepared using cytospin for caspofungin-treated and untreated cells for scanning electron microscopy (SEM) analysis. 16 Biofilms were grown on 10 mm diameter circular coverslips and prepared for SEM analyses as published previously by Chandra et al. 16 After 24 and 72 hours of growth of biofilms, the coverslips were washed with physiological saline, and 0.12 mg/l caspofungin was added to the samples. After 24 hours of antifungal treatment, biofilm containing disks were washed with sterile physiological saline and placed into 2% glutaraldehyde fixative solution. Samples were then dehydrated in a sequence of ethanol (25% ethanol for 15 minutes, 50% ethanol for 15 minutes, 75% ethanol for 15 minutes, 95% ethanol for 15 minutes, then 100% ethanol 3 times for 15 minutes) and dried in a desiccator. Dried preparations were coated with gold and examined using a Hitachi S-4300 electron microscope. [16] [17] Untreated 1-day-old and 3-day-old biofilms were used as controls.
Data analysis
Biofilm mass of C. kefyr clinical isolates was compared to C. albicans SC5314 used as control using the MannWhitney test to enhance comparability to earlier results with other species. Wilcoxon matched-pairs test was used to analyze the differences in fungal damage between planktonic cells and biofilms caused by fluconazole, amphotericin B, caspofungin and micafungin. Data were analyzed using GraphPad Prism 6.05 software. The results were considered significant if the P value was <.05.
Results
Based on the crystal violet assays, the degree of 1-day-old biofilm formation was significantly higher for eight out of 10 C. kefyr clinical isolates (mean of optical density at 540 nm ± standard error of mean: 0.25 ± 0.008) compared to biofilm production of C. albicans SC5314 control strain (0.04 ± 0.002) (P < .01). Isolates 15879 and 32175 were statistically comparable (0.07 ± 0.001) to SC5314 regarding biofilm mass (P > .05). The distribution of MICs for planktonic cells, 1-dayold biofilms and 3-day-old biofilms of the C. kefyr and SC5314 C. albicans reference strain are shown in Table 1 . There are no clinical breakpoints for antifungals against C. kefyr; nevertheless, MIC values of planktonic cells were below the available ECVs for fluconazole (ECV: 1 mg/l) and micafungin (ECV: 0.12 mg/l), respectively (Table 1) . [18] [19] In contrast, caspofungin MICs were above the epidemiological cut-off value (ECV: 0.03 mg/l). ECV for amphotericin B has not been established for C. kefyr. However, the determined MICs for planktonic cells were in the susceptibility range published by Diekema et al. 20 ( Table 1) .
Fluconazole showed lower activity against biofilms compared to amphotericin B or to the tested echinocandins (Table 1 , Fig. 1A and B ). Significant differences were observed in susceptibility between fluconazole-exposed planktonic cells and biofilm-grown cells in case of all C. kefyr isolates, that is, at concentrations between 0.25 and 512 mg/l for early biofilms (P < .01 for all concentrations; Fig. 1A ) and at ≥0.03 mg/l for mature biofilms (P < .01-.05; Fig. 1B ). Based on XTT-based assay, fluconazole showed at least 50% fungal damage at ≥4 mg/l (51.5% ± 6.63% to 78.38% ± 1.44%) and at ≥128 mg/l (57.88% ± 9.2% to 67.25% ± 9.59%) for early and mature biofilms, respectively (Fig. 1A and B) .
In case of amphotericin B, 1-day-old biofilms of all isolates were significantly more resistant at concentrations ranging from 0.12 to 8 mg/l as compared to planktonic cells (P < .01 in all comparisons). Nevertheless, the 50% fungal damage has been detected only at concentration 0.5 mg/l (65% ± 6.7%) or above, the damage increasing in a concentration dependent manner for all isolates (Fig. 1C) . Surprisingly, the three-day-old sessile cells were more susceptible at concentrations ranging from 0.03 to 0.12 mg/l compared to planktonic forms (P < .05) (Fig. 1D) . This was also observed in case of all isolates.
At micafungin concentrations above 0.03 mg/l there was no significant differences in fungal damage between planktonic and 1-day-old sessile cells (P > .05). At least 50% fungal damage was found at ≥0.06 mg/l both for planktonic cells (57% ± 7.0% to 98.88% ± 0.61%) and early stage biofilms (67% ± 9.0% to 98.63% ± 1.24%; Fig. 1E ). In case of mature biofilms 50% fungal damage was observed at ≥0.25 mg/l (74.13% ± 10.77% to 99.38% ± 0.38%). Significantly higher fungal damage was exhibited by planktonic cells compared to mature biofilms at concentrations ranged from 0.06 mg/l to 0.25 mg/l for all isolates (P < .01-.05; Fig. 1F ).
With caspofungin an unexpected susceptibility pattern was revealed ( Fig. 2A and B) . The C. kefyr planktonic cells showed significantly reduced susceptibility at low concentrations as compared to early as well as mature biofilms. Sessile cells were significantly more susceptible at concentrations ranging from 0.015 mg/l to 1 mg/l (P < .01-.05). Moreover, 50% fungal damage was observed first at 0.06 mg/l for both types of biofilms (70% ± 10.0% and 70% ± 11.0% for early and mature biofilms, respectively), while only from 0.5 mg/l (60% ± 3.1% to 100% ± 0%) in case of planktonic cells ( Fig. 2A and B) .
This unexpected susceptibility pattern to caspofungin was confirmed by scanning electron microscopy. Figure 2A and B show the morphological differences of early and mature biofilms of a representative isolate (isolate 15879) at 0.12 mg/l caspofungin. Sessile cells were almost completely eliminated from the early stage biofilm, only cell debris could occasionally be observed ( Fig. 2A) , whereas the untreated control biofilm displayed a large amount of budding yeast cells with normal morphology (Fig. 2A) . In contrast, caspofungin-exposed (0.12 mg/l) planktonic cells displayed normal intact morphology (data not shown). For 3-day-old biofilms, several collapsed yeast cell aggregates with wrinkled surface were detected, which were markedly different from the morphology of the untreated biofilm (Fig. 2B) . In both cases, the observed morphology was in line with the measured fungal damage.
Discussion
C. kefyr is a rare but emerging pathogen with higher prevalence in case of hematological malignancies. 1, 21 The survival rate in intensive care units is significantly lower among patients with C. kefyr infection as compared to patients infected by C. albicans. 22 Previously, a striking seasonality was described in infections caused by C. kefyr that may be explained by the higher rate of contamination of dairy products due to cold chain disturbance in the summer months. 1 Thus, dietary habits may influence the risk of colonization by C. kefyr. Bretagne et al. 4 described a significantly higher rate of central venous catheter associated fungaemia by uncommon yeasts (e.g., C. kefyr) compared with C. albicans. Nonetheless, data regarding biofilm production and antifungal susceptibility of sessile cells against uncommon yeast species including C. kefyr are very limited. The determined MIC values and antifungal activity produced by fluconazole against planktonic cells were in line with previous observations. 1, 6, 23 Based on the present study, the clinically available concentrations of fluconazole 24 may be effective against C. kefyr planktonic cells and early biofilms; however, they may be insufficient against mature biofilms. For 3-day-old biofilms, a concentration of at least 128 mg/l should be achieved at the site of infection in order to produce at least 50% fungal damage. In our fungal damage assays amphotericin B proved to be a very potent antifungal agent at clinically relevant concentrations both against planktonic cells and biofilms. Standard dose of amphotericin B-deoxycholate (1 mg/kg) produces a peak serum concentration ranging from 1.5 to 2.9 mg/l. 25 Based on our findings, this concentration range triggered 98% ± 0.48%, 77% ± 5.88%, and 91% ± 3.12% fungal damage for planktonic cells, early biofilms, and mature biofilms, respectively. However, the prolonged usage of this agent is limited by toxicity. 25 Surprisingly, mature biofilms were significantly more susceptible to amphotericin B compared to planktonic cells at concentrations ranging from 0.03 to 0.12 mg/l. Similarly, Kawai et al. 26 reported that C. tropicalis biofilm is more susceptible than planktonic cells to liposomal amphotericin B; an eightfold difference was reported between planktonic and sessile MICs. However, this phenomenon remains to be explained by further studies. The tested echinocandins generally showed a potent antibiofilm activity without paradoxical growth against sessile C. kefyr. However, the planktonic forms showed an unexpectedly low in vitro susceptibility, especially in case of caspofungin. The MICs of caspofungin for planktonic cells varied from 0.25 to 0.5 mg/l, which is 8-16-fold higher than the ECV (0.03 mg/l). 18 Previously, Jung et al. 2 described that the most frequently isolated species with caspofungin MICs above the ECV was C. kefyr (82%). In addition, this observation was positively associated with the annual usage of echinocandins. Dufresne et al. 1 observed similar rate (88%) of elevated MICs in case of micafungin in patients with hematologic malignancies. Nevertheless, Sanchis et al. 6 showed that caspofungin is more effective in mouse experiments than amphotericin B or fluconazole in spite of higher MIC values; suggesting that MICs of caspofungin do not always reliably predict therapeutic failure. Unfortunately, the lack of in vivo data concerning C. kefyr infections precludes further comparisons. The present study has found very low fungal damage (<50%) at caspofungin concentrations ranging from 0.015 to 0.25 mg/l against planktonic cells. Additionally, there were significant differences between the susceptibility of planktonic and sessile cells between concentrations 0.015 and 1 mg/l, a pattern similar to that seen with amphotericin B. It should be pointed out, however, that poor activity in XTT-based assays is not always equivalent with cell death. For this reason, the results were confirmed by quantitative cfu determination and analysis of fungal morphology using scanning electron microscopy. The number of viable cells derived from biofilms was 2-log lower compared to planktonic cells at concentrations from 0.12 to 1 mg/l (data not shown). Scanning electron microscopy images revealed marked fungal damage among sessile but not in case of planktonic cells. A similar observation was reported by Simitsopoulou et al., 15 who described higher caspofungin activity at low concentrations (0.03-0.5 mg/l) against biofilms formed by C. lusitaniae, C. krusei, and C. parapsilosis as compared to planktonic forms, though these differences were not statistically significant. The exact background responsible for this phenomenon has not been elucidated. Higher number of metabolically inactive stationary-phase planktonic cells may be less susceptible to the cell-wall active echinocandins 27 or a higher rate of apoptosis in caspofungin-treated biofilms may be two plausible explanations for the difference in susceptibilities. 28 A similar observation was reported in case of bacteria by Spoering and Lewis 27 , where the stationary-phase planktonic cells of Pseudomonas aeruginosa were more resistant against the tested antibiotics than biofilms. Notably, these low caspofungin concentrations may be clinically relevant for certain patient populations, which may explain the poorer outcome of C. kefyr infections in some settings, for example, in hematology patients. In neutropenic children, the adjusted mean of trough concentration of caspofungin is only 0.63 mg/l, 29 furthermore, Nguyen et al. 30 measured 0.52 mg/l plasma caspofungin trough concentration in patients in a surgical intensive care unit. These trough concentrations are in the range where the above-mentioned phenomenon was observed, indicating that this may influence clinical efficacy in vivo.
The observed susceptibility pattern of C. kefyr to micafungin was in line with previous studies 15,31 revealing higher activity of micafungin than of caspofungin against planktonic cells and biofilms formed by various nonalbicans Candida species. Significant (>75%) fungal damage was observed, ≥0.25 mg/l micafungin concentrations, both against planktonic and sessile cells. Our data showed that attainable concentrations of micafungin (trough concentration: 1.4-3.1 mg/l) were active against both early and mature biofilms. 32 Interestingly, Seidler et al. 5 reported that micafungin was ineffective even at >16 mg/l against C. kefyr mature biofilms on central venous catheter disks. A limitation of the study is that FKS1 hot-spot sequencing was not performed to exclude the presence of point mutations, which may be associated with reduced caspofungin susceptibility. However, the difference observed between caspofungin and micafungin, together with the known lack of exposure of patients to antifungal therapy before isolation of C. kefyr isolates, renders the existence of such mutations improbable.
In conclusion, our results suggest that the traditionally biofilm-active antifungal agents (amphotericin B, echinocandins) show good activity both against C. kefyr planktonic cells and against biofilms. However, the unexpected susceptibility pattern observed at lower concentrations especially with caspofungin may affect the outcome of infections where planktonic cells are abundantly present, for example, fungemia, at least in certain patient populations. This may be overcome by higher caspofungin doses providing in vivo concentrations higher than those producing this susceptibility pattern. In the future, further comparative in vivo experiments are needed to confirm whether this strange susceptibility pattern of caspofungin is a phenomenon limited to in vitro conditions or has any clinical relevance in the therapy of C. kefyr infections.
